Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects

Neurobiology of Aging

Volumn 35, Issue 2, 2014, Pages 357-364

  Millard, Steven P ^a   Lutz, Franziska ^a,b   Li, Ge ^c   Galasko, Douglas R ^d,e   Farlow, Martin R ^f   Quinn, Joseph F ^g,h   Kaye, Jeffrey A ^g,h   Leverenz, James B ^a,b,c   Tsuang, Debby ^a,c   Yu, Chang En ^a,b   Peskind, Elaine R ^a,c   Bekris, Lynn M ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

A 42; A2M; Alpha 2 Macroglobulin; Alzheimer's disease; APOE; Cerebrospinal fluid

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; CLUSTERIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN CONVERTING ENZYME; GELATINASE B; INSULINASE; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 8; MEMBRANE METALLOENDOPEPTIDASE; MULTIDRUG RESISTANCE PROTEIN 1; PLASMINOGEN; UNCLASSIFIED DRUG;

ADULT; ALPHA 2 MACROGLOBULIN GENE; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; SINGLE NUCLEOTIDE POLYMORPHISM;

A2M; ALPHA-2-MACROGLOBULIN; ALZHEIMER'S DISEASE; APOE; AΒ(42); CEREBROSPINAL FLUID;

AGED; AGED, 80 AND OVER; ALPHA-MACROGLOBULINS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BRAIN; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOLYSIS;

EID: 84887215635     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.07.027     Document Type: Article

References (66)

1. Akuffo E.L., Davis J.B., Fox S.M., Gloger I.S., Hosford D., Kinsey E.E., Jones N.A., Nock C.M., Roses A.D., Saunders A.M., Skehel J.M., Smith M.A., Cutler P. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 2008, 13:618-636.
2. Baulac S., LaVoie M.J., Kimberly W.T., Strahle J., Wolfe M.S., Selkoe D.J., Xia W. Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. Neurobiol. Dis. 2003, 14:194-204.
3. Bekris L.M., Millard S.P., Galloway N.M., Vuletic S., Albers J.J., Li G., Galasko D.R., DeCarli C., Farlow M.R., Clark C.M., Quinn J.F., Kaye J.A., Schellenberg G.D., Tsuang D., Peskind E.R., Yu C.E. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J.Alzheimers Dis. 2008, 13:255-266.
4. Blacker D., Wilcox M.A., Laird N.M., Rodes L., Horvath S.M., Go R.C., Perry R., Watson B., Bassett S.S., McInnis M.G., Albert M.S., Hyman B.T., Tanzi R.E. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 1998, 19:357-360.
5. Breiman, L. 2001. Random forests. Machine Learn 45, 5-32.
6. Brunholz S., Sisodia S., Lorenzo A., Deyts C., Kins S., Morfini G. Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells. Exp. Brain Res. 2012, 217:353-364.
7. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C., Goate A.M., Bales K.R., Paul S.M., Bateman R.J., Holtzman D.M. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 2011, 3:89ra57.
8. Chasseigneaux S., Allinquant B. Functions of Abeta, sAPPalpha and sAPPbeta: similarities and differences. J.Neurochem. 2012, 120(suppl 1):99-108.
9. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
10. Cucullo L., Marchi N., Marroni M., Fazio V., Namura S., Janigro D. Blood-brain barrier damage induces release of alpha2-macroglobulin. Mol. Cell. Proteomics 2003, 2:234-241.
11. Deuss M., Reiss K., Hartmann D. Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17. Curr. Alzheimer Res. 2008, 5:187-201.
12. Edwards T.L., Pericak-Vance M., Gilbert J.R., Haines J.L., Martin E.R., Ritchie M.D. An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B:721-735.
13. Ewers M., Zhong Z., Burger K., Wallin A., Blennow K., Teipel S.J., Shen Y., Hampel H. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008, 131:1252-1258.
14. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between invivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
15. Flachsbart F., Caliebe A., Nothnagel M., Kleindorp R., Nikolaus S., Schreiber S., Nebel A. Depletion of potential A2M risk haplotype for Alzheimer's disease in long-lived individuals. Eur. J. Hum. Genet. 2010, 18:59-61.
16. Francis R., McGrath G., Zhang J., Ruddy D.A., Sym M., Apfeld J., Nicoll M., Maxwell M., Hai B., Ellis M.C., Parks A.L., Xu W., Li J., Gurney M., Myers R.L., Himes C.S., Hiebsch R., Ruble C., Nye J.S., Curtis D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell 2002, 3:85-97.
17. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M.A., Seubert P. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 1998, 55:937-945.
18. Ghebremedhin E., Schultz C., Thal D.R., Del Tredici K., Rueb U., Braak H. Genetic association of argyrophilic grain disease with polymorphisms in alpha-2 macroglobulin and low-density lipoprotein receptor-related protein genes. Neuropathol. Appl. Neurobiol. 2002, 28:308-313.
19. Giometto B., Argentiero V., Sanson F., Ongaro G., Tavolato B. Acute-phase proteins in Alzheimer's disease. Eur. Neurol. 1988, 28:30-33.
20. Hoe H.S., Lee H.K., Pak D.T. The upside of APP at synapses. CNS Neurosci. Therapeut. 2012, 18:47-56.
21. Holm S. Asimple sequential rejective multiple test procedure. Scand. J. Stat. 1979, 6:65-70.
22. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050.
23. Hyman B.T. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch. Neurol. 2011, 68:1062-1064.
24. Kimberly W.T., LaVoie M.J., Ostaszewski B.L., Ye W., Wolfe M.S., Selkoe D.J. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl. Acad. Sci. U.S.A 2003, 100:6382-6387.
25. Koster M.N., Dermaut B., Cruts M., Houwing-Duistermaat J.J., Roks G., Tol J., Ott A., Hofman A., Munteanu G., Breteler M.M., van Duijn C.M., Van Broeckhoven C. The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology 2000, 55:678-684.
26. Li R., Ma L., Huang Y., Zhang Z., Tong T. Characterization of a novel positive transcription regulatory element that differentially regulates the alpha-2-macroglobulin gene in replicative senescence. Biogerontology 2011, 12:517-525.
27. Liao A., Nitsch R.M., Greenberg S.M., Finckh U., Blacker D., Albert M., Rebeck G.W., Gomez-Isla T., Clatworthy A., Binetti G., Hock C., Mueller-Thomsen T., Mann U., Zuchowski K., Beisiegel U., Staehelin H., Growdon J.H., Tanzi R.E., Hyman B.T. Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum. Mol. Genet. 1998, 7:1953-1956.
28. Liaw A., Wiener M. Classification and regression by randomForest. RNews 2002, 2/3:18-22.
29. Licastro F., Parnetti L., Morini M.C., Davis L.J., Cucinotta D., Gaiti A., Senin U. Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1995, 9:112-118.
30. Lim Y.Y., Ellis K.A., Ames D., Darby D., Harrington K., Martins R.N., Masters C.L., Rowe C., Savage G., Szoeke C., Villemagne V.L., Maruff P., Group A.R. Abeta amyloid, cognition, and APOE genotype in healthy older adults. Alzheimers Dement 2012.
31. Liu Z., Zhu H., Fang G.G., Walsh K., Mwamburi M., Wolozin B., Abdul-Hay S.O., Ikezu T., Leissring M.A., Qiu W.Q. Characterization of insulin degrading enzyme and other amyloid-beta degrading proteases in human serum: a role in Alzheimer's disease?. J.Alzheimers Dis. 2012, 29:329-340.
32. Marcello E., Epis R., Saraceno C., Di Luca M. Synaptic dysfunction in Alzheimer's disease. Adv. Exp. Med. Biol. 2012, 970:573-601.
33. Matthijs G., Marynen P. Adeletion polymorphism in the human alpha-2-macroglobulin (A2M) gene. Nucleic Acids Res. 1991, 19:5102.
34. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
35. Miners J.S., Barua N., Kehoe P.G., Gill S., Love S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J.Neuropathol. Exp. Neurol. 2011, 70:944-959.
36. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 1995, 38:643-648.
37. Nicodemus K.K., Malley J.D., Strobl C., Ziegler A. The behaviour of random forest permutation-based variable importance measures under predictor correlation. BMC Bioinformatics 2010, 11:110.
38. Olsson A., Vanderstichele H., Andreasen N., De Meyer G., Wallin A., Holmberg B., Rosengren L., Vanmechelen E., Blennow K. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 2005, 51:336-345.
39. Ozawa D., Hasegawa K., Lee Y.H., Sakurai K., Yanagi K., Ookoshi T., Goto Y., Naiki H. Inhibition of beta2-microglobulin amyloid fibril formation by alpha2-macroglobulin. J.Biol. Chem. 2011, 286:9668-9676.
40. Panza F., Colacicco A.M., D'Introno A., Capurso C., Liaci M., Capurso S.A., Capurso A., Solfrizzi V. Candidate genes for late-onset Alzheimer's disease: focus on chromosome 12. Mech. Ageing Dev. 2006, 127:36-47.
41. Peskind E.R., Li G., Shofer J., Quinn J.F., Kaye J.A., Clark C.M., Farlow M.R., DeCarli C., Raskind M.A., Schellenberg G.D., Lee V.M., Galasko D.R. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch. Neurol. 2006, 63:936-939.
42. Peskind E.R., Riekse R., Quinn J.F., Kaye J., Clark C.M., Farlow M.R., Decarli C., Chabal C., Vavrek D., Raskind M.A., Galasko D. Safety and acceptability of the research lumbar puncture. Alzheimer Dis. Assoc. Disord. 2005, 19:220-225.
43. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
44. Pirttila T., Mehta P.D., Soininen H., Kim K.S., Heinonen O., Paljarvi L., Kosunen O., Riekkinen P., Wisniewski H.M. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. Arch. Neurol. 1996, 53:189-193.
45. Postina R. Acloser look at alpha-secretase. Curr. Alzheimer Res. 2008, 5:179-186.
46. Rehman A.A., Ahsan H., Khan F.H. alpha-2-Macroglobulin: a physiological guardian. J.Cell. Physiol. 2013, 228:1665-1675.
47. Rosenbloom K.R., Dreszer T.R., Pheasant M., Barber G.P., Meyer L.R., Pohl A., Raney B.J., Wang T., Hinrichs A.S., Zweig A.S., Fujita P.A., Learned K., Rhead B., Smith K.E., Kuhn R.M., Karolchik D., Haussler D., Kent W.J. ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res. 2010, 38(database issue):D620-D625.
48. Sagare A.P., Bell R.D., Zlokovic B.V. Neurovascular defects and faulty amyloid-beta vascular clearance in Alzheimer's disease. J.Alzheimers Dis. 2012, 2:1-17.
49. Saunders A.J., Bertram L., Mullin K., Sampson A.J., Latifzai K., Basu S., Jones J., Kinney D., MacKenzie-Ingano L., Yu S., Albert M.S., Moscarillo T.J., Go R.C., Bassett S.S., Daly M.J., Laird N.M., Wang X., Velicelebi G., Wagner S.L., Becker D.K., Tanzi R.E., Blacker D. Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Hum. Mol. Genet. 2003, 12:2765-2776.
50. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359:325-327.
51. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65:403-413.
52. Stockley J.H., O'Neill C. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. Biochem. Soc. Trans. 2007, 35:574-576.
53. Sun X., Wang Y., Qing H., Christensen M.A., Liu Y., Zhou W., Tong Y., Xiao C., Huang Y., Zhang S., Liu X., Song W. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J. 2005, 19:739-749.
54. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289:2094-2103.
55. Tapiola T., Alafuzoff I., Herukka S.K., Parkkinen L., Hartikainen P., Soininen H., Pirttila T. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 2009, 66:382-389.
56. Thal D.R., Schultz C., Botez G., Del Tredici K., Mrak R.E., Griffin W.S., Wiestler O.D., Braak H., Ghebremedhin E. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. Neuropathol. Appl. Neurobiol. 2005, 31:270-279.
57. Verpillat P., Bouley S., Hannequin D., Belliard S., Puel M., Thomas-Anterion C., Dubois B., Agid Y., Campion D., Clerget-Darpoux F., Brice A. Alpha2-macroglobulin gene and Alzheimer's disease: confirmation of association by haplotypes analyses. Ann. Neurol. 2000, 48:400-402.
58. Visser P.J., Verhey F., Knol D.L., Scheltens P., Wahlund L.O., Freund-Levi Y., Tsolaki M., Minthon L., Wallin A.K., Hampel H., Burger K., Pirttila T., Soininen H., Rikkert M.O., Verbeek M.M., Spiru L., Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009, 8:619-627.
59. Wilson M.R., Yerbury J.J., Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol. Biosyst. 2008, 4:42-52.
60. Wu G., Sankaranarayanan S., Tugusheva K., Kahana J., Seabrook G., Shi X.P., King E., Devanarayan V., Cook J.J., Simon A.J. Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. Clin. Biochem. 2008, 41:986-996.
61. Wyatt A.R., Constantinescu P., Ecroyd H., Dobson C.M., Wilson M.R., Kumita J.R., Yerbury J.J. Protease-activated alpha-2-macroglobulin can inhibit amyloid formation via two distinct mechanisms. FEBS Lett. 2013, 587:398-403.
62. Yerbury J.J., Kumita J.R., Meehan S., Dobson C.M., Wilson M.R. alpha2-Macroglobulin and haptoglobin suppress amyloid formation by interacting with prefibrillar protein species. J.Biol. Chem. 2009, 284:4246-4254.
63. Yerbury J.J., Wilson M.R. Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake. Cell Stress Chaperones 2010, 15:115-121.
64. Zabel M., Schrag M., Crofton A., Tung S., Beaufond P., Van Ornam J., Dininni A., Vinters H.V., Coppola G., Kirsch W.M. Ashift in microglial beta-amyloid binding in Alzheimer's disease is associated with cerebral amyloid angiopathy. Brain Pathol. 2013, 23:390-401.
65. Zetterberg H., Andreasson U., Hansson O., Wu G., Sankaranarayanan S., Andersson M.E., Buchhave P., Londos E., Umek R.M., Minthon L., Simon A.J., Blennow K. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 2008, 65:1102-1107.
66. Zhang R., Barker L., Pinchev D., Marshall J., Rasamoelisolo M., Smith C., Kupchak P., Kireeva I., Ingratta L., Jackowski G. Mining biomarkers in human sera using proteomic tools. Proteomics 2004, 4:244-256.